CPRX250117P15000
- 0.00
- 0.000.00%
Catalyst Pharmaceuticals Newsroom
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31
Express News | Catalyst Pharmaceuticals Announces Sub-Licensee Dydo Pharma Launched Firdapse® in Japan
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in Japan
Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Are Robust Financials Driving The Recent Rally In Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock?
Express News | Catalyst Pharmaceuticals: 2024 Total Net Rev Slightly Exceed Upper End of Latest Guidance
HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35
H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Raises Target Price to $35
Catalyst Pharmaceuticals Price Target Maintained With a $30.00/Share by B of A Securities
Catalyst Pharmaceuticals Analyst Ratings
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $29
Citi Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31
Catalyst Pharmaceuticals Secures Patent Victory: Analyst Reaffirms Buy Rating With 58.7% Upside Potential
Sector Update: Health Care Stocks Higher in Afternoon Trading
Catalyst Pharmaceuticals in Settlement With Teva of Firdapse Patent Litigation
Express News | Catalyst Pharmaceuticals Inc - Penging Firdapse Patent Litigation Against Hetero and Lupin Ongoing
Catalyst Pharmaceuticals Announces Settlement Of FIRDAPSE Patent Litigation With Teva Pharmaceuticals; Teva Will Not Market Its Generic Version Of FIRDAPSE In The U.S. Any Earlier Than February 25, 2035, If Approved By The FDA
Catalyst Pharmaceuticals Halts Stock Trading Pending Material News Release